Innovative Diagnostic Tool Cognision offers the FDA-cleared COGNISION System, a user-friendly, cloud-based EEG/ERP platform designed for neurocognitive assessments, making it highly suitable for clinics and healthcare providers seeking advanced diagnostic solutions for conditions like dementia and traumatic brain injuries.

Expanding Data Integration With the launch of Cognision360, the company consolidates multiple neurobiomarker data streams into a single platform, opening opportunities to partner with pharmaceutical companies and clinical research organizations involved in CNS drug development and biomarker qualification.

Strategic Industry Position As a founding member of the EEG/ERP Biomarker Qualification Consortium and with its deployment in multiple clinical trials, Cognision is well-positioned to collaborate with leading research institutions and biotech firms focused on neurodegenerative and neuropsychiatric disorder diagnostics.

Recent Product Launch The recent launch of Cognision360 demonstrates technological innovation and growth, creating prospects to target pharma and CROs interested in integrating neurobiomarkers into their CNS therapeutic trials.

Growth and Funding With revenue estimated between 1 million and 10 million dollars and a funding of 2 million dollars, Cognision presents a valuable opportunity for investors and partners seeking to expand in the neurodiagnostic and CNS drug development markets.